R&D leaders face a persistent challenge: making high-stakes investment decisions in an environment where the most consequential threats and opportunities are often the least visible. AI is changing what’s possible, but not always in the ways people expect.
Join Digital Science for this session exploring what enterprise R&D leaders have learned about using AI to guide strategic decisions. In this session, you will learn:
Why generative AI alone won’t surface the unknown unknowns that matter most, and what structured intelligence — knowledge graphs, ontologies and semantic models — makes possible that keyword searches and LLMs cannot.
How AI can introduce productive doubt into decision-making, generating evidence-backed alternative hypotheses that help leaders move past confirmation bias without triggering defensiveness.
What new content-derived metrics look like in practice, and why cross-industry benchmarking and real-time validation are replacing backward-looking indicators for evaluating novel investments.
Access this on-demand webinar now to hear how R&D leaders across pharmaceutical, chemical and technology enterprises are rethinking the role of AI in strategic decision-making.